Subscribe

Findings from the Connect MM Registry: Changes in Treatment Patterns in Patients with Newly Diagnosed Multiple Myeloma

Conference Correspondent - Conference Correspondent, ASH 2016 - Multiple Myeloma

In this analysis of multiple myeloma (MM) treatment patterns, researchers used Connect MM, the first and largest prospective, observational, US-based, multicenter disease registry designed to characterize treatment patterns and outcomes for patients with newly diagnosed MM (NDMM). Patients with NDMM were enrolled in 2 sequential cohorts from September 2009 to April 2016. Study sites represented all census regions to allow reasonable generalizability of the findings.

Study enrollment was initiated at 250 community and academic sites. Cohort 1 enrolled 1493 NDMM patients from September 2009 to December 2011, and cohort 2 enrolled 1518 NDMM patients from December 2012 to April 2016. Data were collected at a baseline visit and quarterly visits thereafter until death or discontinuation. The study examined induction and maintenance treatment patterns by age group and stem-cell transplant (SCT) status.

The median age was 67 years (range, 24‐94), 58% of patients were male, 83% were white, and 38% had stage III MM. Median patient follow‐up was 39.3 months in cohort 1 and 15.4 months in cohort 2. A total of 553 (19.4%) patients had received SCT. The Table shows the most common induction, maintenance, and second-line regimens by patient subgroups in order of decreasing frequency of use.

Table

Researchers reported an increase in the use of triplet regimens over time in first-line induction regardless of age. Monotherapy dominated maintenance therapy for patients regardless of SCT status; the most common maintenance regimens included lenalidomide.

Rifkin RM, et al. ASH 2016. Abstract 4489.

Related Items
Omadacycline for Acute Bacterial Skin and Skin Structure Infections: Integrated Analysis of Randomized Clinical Trials
December 2018 Vol 11, No 9 published on December 27, 2018 in Conference Correspondent
Improved Quality of Life in Adults with Acute Bacterial Skin and Skin Structure Infections with Omadacycline or Linezolid Therapy
December 2018 Vol 11, No 9 published on December 27, 2018 in Conference Correspondent
Omadacycline In Vitro Activity Against a Molecularly Characterized Collection of Clinical Isolates with Known Tetracycline Resistance Mechanisms
December 2018 Vol 11, No 9 published on December 27, 2018 in Conference Correspondent
Integrated Safety Summary of Omadacycline, A Novel Aminomethylcycline Antibiotic
December 2018 Vol 11, No 9 published on December 27, 2018 in Conference Correspondent
Sustained Response Following Discontinuation of MTX in Subcutaneous Tocilizumab-Treated Patients with RA
Conference Correspondent published on November 9, 2017 in ACR 2017, Conference Correspondent
Last modified: May 17, 2017
Copyright © Engage Healthcare Communications, LLC. All rights reserved.